The use of continuous-infusion in outpatient setting could be widely used in oncology and haematology care. Many times the lack of data stability about single drug or admixture of drugs, together with patient education and safety, make difficult the transition from inpatient to outpatient setting. Nowadays, this is a big challenge for hospital pharmacists, who must take into consideration the critical issues related to chemical and physical stability, besides microbiological one, in order to ensure high quality preparations and guarantee the safety and quality of care, to protect patients and their health. The aim of this article is to highlight the critical issues concerning the transition from inpatient to outpatient setting, with particular interest regarding chemotherapy protocols, which require preparation with long-term continuous-infusion.
SvirskisDBeheraSNaidooN, et al.
Stability of vincristine sulfate, doxorubicin hydrochloride and etoposide phosphate admixtures in polyisoprene elastomeric pump supporting transition of the EPOCH regimen to outpatient care. J Oncol Pharm Pract2018;
25: 831–840.
2.
DunleavyKPittalugaSMaedaLS, et al.
Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma.N Engl J Med2013;
368: 1408–1416.
3.
SanfilippoRBertulliRMarrariA, et al.
High-dose continuous-infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcoma.Clin Sarcoma Res2014;
4: 16.
4.
SalmanDSwindenJBartonS, et al.
Evaluation of the stability profile of anticancer drugs: a review of ifosfamide and Mesna regimen for the treatment of metastatic soft tissue sarcoma.J Oncol Pharm Pract2016;
22: 86–91.
5.
MartinALFrankJPWaggonerML.Making moves: transitioning R-EPOCH to the ambulatory setting. J Oncol Pharm Pract2018;
24: 617–622.
6.
EvansSSGandhiASClemmonsAB, et al.
Clinical and cost comparison evaluation of inpatient versus outpatient administration of EPOCH-containing regimens in non-Hodgkin lymphoma. J Pharm Pract2017;
30: 400–405.
7.
WolfeJLThomaLADuC, et al.
Compatibility and stability of vincristine sulfate, doxorubicin hydrochloride, and etoposide in 0.9% sodium chloride injection.Am J Health Syst Pharm1999;
56: 985–989.
8.
YuanPGrimesGJShankmanSE, et al.
Compatibility and stability of vincriste sulfate, doxorubicin hydrochloride, and etoposide phosphate in 0.9% sodium chloride injection.Am J Health Syst Pharm2001;
58: 594–598.
9.
LoefflerTMWeberFWHausamenTU.Ambulatory high-dose 5-days continuous-infusion ifosfamide combination chemotherapy in advanced solid tumors: a feasibility study. J Cancer Res Clin Oncol1991;
117: S125–S128.
10.
RadfordJAMargisonJMSwindellR, et al.
The stability of ifosfamide in aqueous solution and its suitability for continuous 7-days infusion by ambulatory pump. J Cancer Res Clin Oncol1991;
117: S154–S156.
11.
ZhangYKawediaJDMyersAL, et al.
Physical and chemical stability of high-dose ifosfamide and mesna for prolonged 14-days continuous infusion.J Oncol Pharm Pract2014;
20: 51–57.
12.
SalmanDSwindenJBartonS, et al.
Evaluation of the stability profile of anticancer drugs: a review of ifosfamide and mesna regimen for the treatment of metastatic soft tissue sarcoma.J Oncol Pharm Pract2016;
22: 86–91.
13.
Blyncito®. Blinatumumab for Injection. Italy: Amgen Europe B.V., 2019.
HenryDWMarshallJLNazzaroD, et al.
Stability of cisplatin and ondansetron hydrochloride in admixtures for continuous infusion.Am J Health Syst Pharm1995;
52: 2570–2573.
16.
CoatesAGebskiVBishopJF, et al.
Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies.N Engl J Med1987;
317: 1490–1495.
17.
MoodyDG.External ambulatory infusion devices and the oncology patient. J Pharm Tech1986;
2: 160–165.
18.
LokichJJZipoliTEMooreC, et al.
Doxorubicin/vinblastine and doxorubicin/cyclophosphamide combination chemotherapy by continuous infusion. Cancer1986;
56: 1020–1023.
19.
PristonMSewellG.Stability of three cytotoxic drug infusions in the Graseby 9000 ambulatory infusion pump. J Oncol Pharm Pract1998;
4: 143–149.
20.
LeghaSSBenjaminRSMackayB, et al.
Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion.Ann Intern Med1982;
96: 133–139.
21.
SeifertPBakerLHReedML, et al.
Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer1975;
36: 123–128.
22.
MortimerJAndersonI.Managing the toxicities unique to high-dose leukovorin (CF) and fluorouracil (FU). Proc Am Clin Oncol1989;
8: 98.
23.
ZhaoHYGuJLyuJ, et al.
Pharmacokinetic and pharmacodynamics efficacies of continuous versus intermittent administration of meropenem in patients with severe sepsis and septic shock: a prospective randomized pilot study.Chin Med J2017;
130: 1139–1145.
24.
LeijenSVeltkampSAHuitemaADR, et al.
Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate of gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer.Gynecol Oncol2013;
130: 511–517.
25.
PlunkettWHuangPGhandiV.Metabolism and action of fludarabine phosphate. Semin Oncol1990;
17: 3–17.
26.
AustinPDEliaM.A systematic review and meta-analysis of the risk of microbial contamination of aseptically prepared doses in different environments.J Pharm Pharm Sci2009;
12: 233–242.
27.
AustinPDHandKSEliaM.Systematic review and meta-analysis of the risk of microbial contamination of parenteral doses prepared under aseptic techniques in clinical and pharmaceutical environments: an update.J Hosp Infect2015;
91: 306–318.
28.
RapsilberLCamp-SorrellD.Ambulatory infusion pumps: application to oncology.Sem Oncol Nurs1995;
11: 213–220.
29.
PolinskiJMKowalMKGagnonM, et al.
Home infusion: safe, clinically effective, patient preferred, and cost saving.Healthcare2017;
5: 68–80.
30.
LarsenFOChristiansenABRishojA, et al.
Safety and feasibility of home-based chemotherapy. Dan Med J2018;
65: A5482.
